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The  mechanisms by which insulin-like growth factor-I 
(IGF-I) is released from insulin-like growth factor bind- 
ing proteins (IGFBPs) and  then binds to its receptor 
have not been  defined.  This study was  designed to de- 
termine the role of glycosaminoglycans in  altering  the 
formation of the IGF-I*IGFBP  complexes. Heparin inhib- 
ited formation of the IGF-1-IGFBP-5  complex and also 
separated preformed  IGF-IsIGFBP-5  complexes. Heparin 
also inhibited formation of the IGF-I-IGFBP-3  complex; 
however, it did  not inhibit formation of complexes  be- 
tween  IGF-I and IGFBP-l, -2, or -4. Heparin exposure was 
associated with a 17-fold decrease in  the affinity of IG- 
FBP-5 for IGF-I. A synthetic peptide that contains resi- 
dues from Ar8’l t0Ar8~’ of IGFBP-5, and a heparin bind- 
ing domain prevented the inhibitory effects of heparin 
on formation of the IGF-I*IGFBP-5  complex. It did not 
directly compete  with  IGF-I for binding to IGFBP-5,  sug- 
gesting that  heparin binding to this region of  IGFBP-5 
resulted in a conformational change in IGFBP-5  which 
lowered its affinity for IGF-I. Other glycosaminoglycans 
that contained 0-linked sulfates in the 2 or 3 carbon po- 
sitions of iduonic acid, e.g. heparan sulfate and derma- 
tan sulfate, also inhibited the IGF-1-IGFBP-5 complex 
formation, whereas those that did not, such as  keratan 
sulfate or hyaluronic acid, had minimal  effects.  Anionic 
polysaccharides that contained 0-sulfate groups in  the 2 
or 3 positions, such as dextran sulfate, pentosan polysul- 
fate, and fucoidan,  also had inhibitory activity.  The find- 
ings suggest a role for these compounds in inhibiting 
IGF-1-IGFBP interactions, thus making  IGF-I available 
to bind to its receptor. 
Insulin-like growth factor I (IGF-I)’ cellular actions have 
been  shown  to be exerted  through the binding of IGF-I  to its 
receptor  (1);  however,  most of IGF-I in extracellular  fluids  is 
bound  to  insulin-like  growth  factor  binding  proteins  (IGFBPs). 
The  IGFBPs  have  been  shown  to stimulate or to  inhibit  IGF- 
I-mediated  cellular  actions (2-4). Binding of IGF-I  to high af- 
finity  forms of IGFBPs  in  conditioned  medium  prevents it from 
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binding  to its receptor,  thereby  inhibiting IGF-I mediated cel- 
lular actions  (4, 5) .  On the  other  hand, the binding of IGF-I to 
cell  surface  or  extracellular  matrix (ECM) associated  IGFBPs 
has been  associated with potentiation of IGF-I’s cellular  actions 
(3, 5-7). In both  situations it remains  uncertain  how  IGF-I  is 
released  from  IGFBPs  in  extracellular  fluids or on  cell  surfaces 
in order to be able to bind to its receptor, an event that is 
usually  required  for  optimal biologic responses. 
Recently  glycosaminoglycans (GAGS) and  proteoglycans 
have  been  shown  to  modulate  growth  factor-stimulated  cellular 
actions (8, 9).  Basic  fibroblast  growth  factor  (b-FGF)  binds  to 
bovine  capillary  endothelial  cell  surface  heparin-like mol- 
ecules, which act as a reservoir of b-FGF and modulate  the 
metabolism of b-FGF  by  cells (10). The biological half-life of 
acidic  FGF is prolonged  by  heparin,  thereby  enhancing  its cel- 
lular  actions (11). Transforming  growth  factor p stimulates  syn- 
thesis of decorin (9) and  when  transforming  growth  factor p is 
bound  to  decorin  its biological activity is decreased (12). 
Heparin  binding sites in many  proteins  have  been  charac- 
terized and shown  to  contain  multiple  basic  amino  acids. Two 
motifs X-B-B-X-B-X and X-B-B-B-X-X-B-X (B: basic  amino  acid, 
X. nonbasic  amino  acid)  have  been  proposed as consensus se- 
quences  for  heparin  binding. All of the forms of IGFBPs  except 
for  IGFBP-4  have at lease  one of these  putative  heparin  bind- 
ing  sequences  (13,141,  suggesting that they  have the potential 
to  bind  to  heparin.  Previous tudies have  shown that heparin 
can  interfere  with e formation of the  IGF-I.IGFBP-3  complex 
(15, 16); therefore,  we  wondered  whether  heparin  might  affect 
the binding of IGF-I  to  other  forms of IGFBPs. We report  here 
that heparin  inhibited  the  IGF-I.IGFBP-5  complex  formation 
but  had no effect on binding to IGFBP-1, -2, or -4. We have 
determined some of the structural requirements of heparin 
that are  necessary  for  its  inhibitory  activity  and  have  defined a 
region of IGFBP-5 that mediates  heparin-induced  inhibition of 
IGF-I  binding. 
EXPERIMENTAL PROCEDURES 
Materials-Recombinant human IGFBP-3,  IGFBP-4, and IGFBP-5 
were synthesized in transfected Chinese hamster ovary  cells and puri- 
fied as described  previously (17). Recombinant human IGFBP-1(5) and 
bovine  IGFBP-2 (18) were prepared as published previously.  Recombi- 
nant IGF-I  was obtained from  Bachem,  Inc.  (Torrance,  CA).  1251-IGF-I 
was a gift from Dr.  Louis E. Underwood (University of North Carolina, 
Chapel Hill). 1251-IGFBP-5 was prepared by a modified chloramine-T 
method (19). Three peptides that contain sequences of IGFBP-5  were 
synthesized and purified as described (20). They  were designated pep- 
tide A (residues RzZ1-K-G-F-Y-K-R-K-Q-C-K-P-S-R-G-R-K-Rz3’), peptide 
B (residues A151-V-K-K-D-R-R-K-K-L-T’61), and peptide D (residues 134P- 
K-I-F-R-P-K-H-T-R-I-S-E-L-K-A-E160), respectively. Heparin (187 USP 
unitdmg) was purchased from Sigma. Heparin, heparan  sulfate, chon- 
droitin sulfate A, chondroitin sulfate C, dermatan sulfate, hyaluronic 
acid, and keratan sulfate were purchased from Seikagaku Kogyo Co. 
(Tokyo, Japan). Chemically modified heparins, including completely 
desulfated, N-acetylated heparin (CDSNAc-heparin),  completely desul- 
fated, N-resulfated heparin (CDSNS-heparin), and N-desulfated, N- 
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acetylated heparin (NDSNAc-heparin) were purchased from Seikagaku 
Kogyo Co. Dextran sulfate (My: <10,000), pentosan polysulfate, and 
fucoidan were purchased from Sigma. Dithiothreitol was purchased 
from Sigma. Disuccinimidyl suberate (DSS) was purchased from Pierce 
Chemical Co. Dimethyl sulfoxide was purchased from Mallinckrodt 
Chemical Co. (Paris, KY). Eagle's minimum  essential medium (EMEM) 
was purchased from Hazelton (Denver, PA). 
Affinity Cross-linking Studies-Cross-linking was performed accord- 
ing to  a modification methods described previously (21,22). '2sII-IGF-I or 
'2sI-IGFBP-5 (30,000 cpdtube) was added to 100 p1  of  EMEM supple- 
mented  with 20 mM HEPES, pH 7.3, and was  incubated a t  room tem- 
perature with IGFBP-1, -2, -3, -4, or -5 (100 ng/ml) or unlabeled IGF-I 
(100 ng/ml). Additional incubations were conducted using '2sI~IGF-I  and 
heparan sulfate, chondroitin sulfate  A or C, dermatan sulfate, keratan 
sulfate, or hyaluronic acid using 200 pg/ml. Chemically modified hepa- 
rins, dextran sulfate, pentosan polysulfate, and fucoidan were also 
tested a t  100 or 200 pg/ml. The  synthetic peptides containing IGFBP-5 
sequences termed peptides A, B, or D were tested a t  concentrations 
between 0.27 and 27 p ~ .  After a  1-h  incubation the samples were cross- 
linked by the addition of 10  pl of 5 mM DSS, which had been dissolved 
in dimethyl sulfoxide, to give a  final concentration of 0.5 mM DSS for 20 
min. The reaction was stopped by adding 10 p1  of 0.5 M Tris-HC1, pH 7.4. 
Samples for SDS-PAGE were exposed to dithiothreitol in a final con- 
centration of 0.1 M and Laemmli sample buffer (23). They were electro- 
phoresed through  a 12.5%  gel. The gels were fixed with 25% isopropanol 
containing 10% acetic acid and 2.5% glycerol for 30 min then dried and 
autoradiographed  using Kodak X-Omat film. In some experiments the 
autoradiographic  intensities of radiolabeled bands were determined by 
scanning densitometry using a Hoffer scanning densitometer, model 
'z,51GF-Z Binding Assay-To determine the affinity of the IGFBPs for 
IGF-I, lZ5I-IGF-I (20,000 CPWtube) was incubated with 8 ng/ml of each 
form of IGFBP in 0.25 ml of 0.05 M HEPES, 0.1% bovine serum albumin, 
pH 6.0. Duplicate tubes received increasing  concentrations of unlabeled 
IGF-I (0.4-10 ng/ml) and some tubes also received heparin 10 pg/ml. 
The bound and free IGF-I were separated by precipitation  using 12.5% 
polyethylene glycol (M, 8000-12,000) (Sigma) as described previously 
(5). The data were analyzed according to the method of Scatchard. 
Binding of IGFBPs to Heparin-To determine if each form of IGFBP 
could bind to heparin, 4 pg/ml of each was incubated with heparin 
sepharose beads (5 pl) (Pharmacia Biotech Inc.) in EMEM, supple- 
mented with 20 mM HEPES  and 0.02% Tween 20, pH 7.3, in a final 
volume of 50 pl. To correct for nonspecific binding duplicate tubes con- 
taining an equal amount of IGFBP, and Sepharose  beads but no heparin 
were included. After an overnight incubation a t  4 "C, the samples were 
centrifuged at  16,000 x g for 1 min. The supernatants (24 p1) were 
electrophoresed using  a 12.5% SDS gel then ligand blotted and autora- 
diographed. The pellets were washed with 200 pl of the  same buffer 
then incubated for 10 min a t  60 "C in 35 pl of Laemmli sample buffer 
then centrifuged. The IGFBPs in  these  supernatants were also ana- 
lyzed by ligand blotting. 
GS-300. 
RESULTS 
Heparin was shown to inhibit formation of the '251-IGF- 
IeIGFBP-5  complex (Fig. lA). '251-IGF-I migrated  to the bottom 
of the gel, whereas when it was incubated with IGFBP-5, a 
band with an approximate molecular mass of 47 kDa was de- 
tected. Labeling of this band could  be inhibited if unlabeled 
IGF-I was added, indicating that  the cross-linking of  '251-IGF-I 
to IGFBP-5 was specific. Increasing concentrations of heparin 
reduced intensity of the 47-kDa band,  indicating that heparin 
inhibited '251-IGF-I.IGFBP-5  complex formation. Scanning 
densitometry showed that  the band  intensity  was reduced 56% 
with 1.0 pg/ml heparin and 83% with 100 pg/ml. In order to 
confirm the results, '251-IGFBP-5 was  incubated  without (lane 
1 ) or with (lanes 2-7) 100 ng/ml of IGF-I in  the absence (lanes 
1, 2,  and  7) or presence (lanes 3-6) of the indicated concentra- 
tions of heparin (Fig. B). When '251-IGFBP-5 was  incubated 
without IGF-I, two bands  with molecular mass  estimates of 39 
and 23 kDa were detected. When '251-IGFBP-5 was  incubated 
with IGF-I, a 47-kDa band was detected in addition to the 
molecular mass 39 kDa and  the 23-kDa bands. However, in  the 
presence of heparin the  intensity of the 47-kDa band  was de- 














FIG. 1. A, inhibitory effects of heparin on forming the Iz5I-IGF- 
1.IGFBP-5 complex. '2sI-IGF-I (30,000 cpdtube) was added to 100 pl of 
EMEM supplemented with 20 mM HEPES, pH 7.3. The  mixture was 
incubated with 100 ng/ml of IGFBP-5 and  the indicated concentrations 
of heparin a t  room temperature. After a 1-h incubation,  samples were 
cross-linked by adding DSS in a final concentration of  0.5 mM for  20 min 
and  then  the reaction was stopped by addition of 10 pl of 0.5 M Tris-HC1, 
pH 7.4. Samples for  SDS-PAGE were prepared in a final concentration 
of 0.1 M of dithiothreitol and  in Laemmli sample buffer, then electro- 
phoresed through  a 12.5% gel. The gel was fixed with 25% isopropanol 
containing 10% acetic acid and 2.5% glycerol, dried, and autoradio- 
graphed. Lane 1, no IGFBP-5; lanes 2-7, IGFBP-5, 100 ng/ml; lune 3, 
heparin, 1.0 pg/ml; lane 4, heparin, 2.5 pg/ml; lune 5, heparin, 10 pg/ml; 
lane 6, heparin, 100 pg/ml; lane 7, unlabeled IGF-I, 100 ng/ml. B, 
inhibitory effects of heparin on formation of the '251-IGFBP-5.1GF-I 
complex. '2sI-IGFBP-5 (30,000 cpdtube) was added to 100 p1  of EMEM 
supplemented with 20 mM HEPES, pH 7.3, and incubated with 100 
ng/ml of IGF-I and  the indicated concentrations of heparin a t  room 
temperature. After a  1-h  incubation,  samples were cross-linked using 
DSS, electrophoresed, and autoradiographed as  described in  the legend 
to Fig. LA. The upper arrow  represents  the '2sII-IGF-I.IGFBP-5 complex, 
and  the lower arrow represents 'ZsI-IGFBP-5. Lune 1, no IGF-I; lanes 
2-7, IGF-I, 100 ng/ml; lane 3, heparin, 1 pg/ml; lane 4,  heparin, 2.5 
pg/ml; lane 5, heparin, 10 pg/ml; lane 6, heparin, 100 pg/ml; lane 7, 
unlabeled IGFBP-5, 100 ng/ml. 
indicating that  heparin inhibited formation of the IGF- 
IeIGFBP-5  complex. The molecular weight estimate of IGFBP-5 
was larger  than  that previously reported  using nonreduced gels 
(15). When the molecular mass of lZ5I-IGFBP-5 was determined 
under reducing and nonreducing conditions, molecular mass 
estimates of 39 and  31 kDa, respectively, were obtained (data 
not shown). The 31-kDa estimate agrees with that obtained 
previously using nonreducing conditions (5). 
To determine the specificity of the effect of heparin on IGF-I 
complex formation with IGFBP-5, the effect of heparin on the 
cross-linking of  '251-IGF-I to IGFBP-1, IGFBP-2, IGFBP-3, and 
IGFBP-4 was examined. '251-IGF-I was incubated with 100 
ng/ml of each form of IGFBP in  the presence or absence of 100 
yg/ml of heparin. When the IGFBPs were incubated with 1251- 
IGF-I in  the absence of heparin, the IGF-I.IGFBP complexes 
were detected (Fig. 2). When heparin  was added, the  intensity 
of the '251-IGF-I.IGFBP-3 complex band was decreased (43% 
reduction by scanning  densitometry) but  the intensities of the 
'251-IGF-I-IGFBP-1, -2, or -4  complex bands were not changed, 
e.g. 107, 112 and 102% of control, respectively.  If the  heparin 
concentration was increased to 500 pg/ml, a 57% reduction in 
'251-IGFBP-3 band intensity was noted, but there was no 
change in  the  intensity of the IGF-1-IGFBP-4  complex (data not 
shown). To determine if these differences were due to the ability 
of each of the IGFBPs to bind to  heparin, each form of IGFBP 
was  incubated  with  heparin-Sepharose beads, and  the  amount 
of IGFBP bound to heparin was determined by SDS-PAGE 
followed  by ligand blotting. As shown in Fig. 3 heparin-Sepha- 
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FIG.  2. Inhibitory effects of heparin  on the binding of the IGF-I 
to other forms of IGFBPs. '251-IGF-I (30,000 cpdtube)  was  incubated 
with 100 ng/ml of IGFRP-1, IGFBP-2,  IGFBP-3,  IGFBP-4,  or  IGFBP-5 
in  the presence or absence of 100 pg/ml of heparin  at room temperature 
in 100 pl of EMEM supplemented 20 mM HEPES,  pH 7.3. After 1 h the 
samples were cross-linked using DSS as  described previously, then 
SDS-PAGE was  performed  under  reducing  conditions,  and  the  products 
5, IGFBP-4; lanes 6-8, IGFBP-1; lanes 9-11, IGFBP-2; lanes 12-14, 
were analyzed by autoradiography. Lanes 1 3 ,  IGFBP-3; lanes 4 and 
IGFBP-5. Lanes 2, 5, 7, 10, and 13, heparin, 100 pg/ml. Lanes 3, 8, 11, 
and 14, unlabeled IGF-I,  100  ng/ml. 











FIG. 3. Binding of IGFBPs to heparin. Each form of IGFBP (4 
pg/ml)  was  incubated  with  heparin-Sepharose  beads (5 p1) as described 
under "Experimental Procedures." The mixture was centrifuged, and 
the  bound  IGFBPs  were  released from the  beads by heating  to 60 "C for 
rated by SDS-PAGE, transferred  to Immobilon filters,  and  ligand-blot- 
10 min.  in  Laemmli  sample buffer. The  released  proteins  were  sepa- 
ted.  The upperpanel shows  the  IGFBPs  remaining  in  the  supernatants, 
whereas  the lower  panel shows  the  amount of each  IGFBP  that  was 
2, 4, 6, 8, and 10). Lanes 1 and 2, IGFBP-1; lanes 3 and 4, IGFBP-2; 
bound  to  sepharose (lanes I ,  3,5,  7, and 9) or heparin-Sepharose (lanes 
lanes 5 and 6 ,  IGFBP-3; lanes 7 and 8, IGFBP-4; lanes 9 and 10, 
IGFBP-5. 
rose  bound  IGFBP-3, -4, and -5 but,  not IGFBP-1 or -2. Since 
IGFBP-3, -4, and -5 bound heparin,  but  heparin  inhibited  the 
cross-linking of IGF-I to only IGFBP-3 and -5, we wished to 
determine the mechanism by which heparin was inhibiting 
IGF-I binding. Increasing concentrations of unlabeled IGF-I 
were incubated  with 1251-IGF-I and IGFBP-5  (8.0  ng/ml) in  the 
presence or  absence of heparin,  and  the bound  IGF-I was pre- 
cipitated using polyethylene glycol. Scatchard  analysis of the 
binding  data showed that coincubation with  heparin  (10 pg/ml) 
decreased the affinity of IGFBP-5 for IGF-I by 17-fold (Fig.  4). 
In  contrast 10 pg/ml of heparin  had no effect on the affinity of 
IGFBP-4 for IGF-I and  resulted  in only a 2-fold reduction in  the 
affinity of IGFBP-3 (data not  shown). 
Since most of IGF-I is bound to IGFBPs in extracellular 
fluids, it  is important  to clarify whether  heparin  separates  the 
IGF-1.IGFBP-5 complexes that  have  already formed. 12sI-IGF-I 
was  incubated  with 100 ng/ml of IGFBP-5 at room temperature 
(Fig. 5). After a 1-h incubation,  the  samples were exposed to 100 
pg/ml of heparin (lanes 3, 5 ,  and 7) or heparin  was  omitted 
(lunes 2, 4, and 6). The  samples were then  incubated for an 
additional 15 min (lanes 2 and 3), 30 min (lanes 4 and 5 ) ,  or 60 
min (lanes 6 and 7). After the  first 1-h incubation,  the IGF-I- 
.IGFBP-5 complex was formed. Subsequent incubation with 
heparin separated this complex, since band intensities were 
decreased by 86,91,  and 9396, respectively, compared with  that 
in  the paired control sample  without  heparin.  The  separation f 
p " J  
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FIG. 4. Scatchard plot of the effect of heparin on the  binding of 
IGF-I to IGFBP-5. '"'I-IGF-I (20,000 cpm)  and  IGFBP-5 (8 ng/ml)  and 
increasing concentrations of unlabeled IGF-I were incubated in the 
presence (0) or absence (0) of 10 pg/ml heparin  overnight a t  4 "C as  
described  under  "Experimental  Procedures."  Bound  and  free  IGF-I  were 
separated by precipitation  with  12.59  polyethylene glycol and centrifu- 
gation.  The  data  are plotted  using  the  method of Scatchard. 
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FIG. 5.  Time course of heparin-induced separation of the IGF- 
IeIGFBP-5 complex. '*"I-IGF-I (30,000 cpdtube)  was added  to  100 p1 
of EMEM  supplemented  with  20 mM HEPES,  pH 7.3, and  incubated 
with  100  ng/ml of IGFBP-5 a t  room temperature.  After  a  1-h  incubation, 
selected  samples  were exposed to  heparin, 100 pg/ml (lanes 3, 5, and 7) 
(lanes 2, 4, and 6, no heparin)  and  then  incubated for another 15 min 
(lanes 2 and 31, 30  min (lanes 4 and 5), and 60 min (lanes 6 and 7), 
respectively. At the  indicated  times,  the  samples  were  cross-linked  and 
then electrophoresed and  autoradiographed as described  in  the  legend 
to Fig. 1A. 
the  IGF-I-IGFBP-5 complex by heparin  was  nearly complete by 
15 min. 
The effects of other GAGS on the inhibition of IGF-I.IGFBP-5 
complex formation  were  examined. The  intensity of the 47-kDa 
band  in  the  samples  was decreased by heparin,  heparan  sul- 
fate,  or  dermatan  sulfate compared with control (Fig.  6). The 
experiment  was  repeated seven times  and  the  mean reductions 
in  band  intensities compared with control were heparin, 84.7 2 
6.6% ( p  c 0.001); heparan sulfate 78.2 2 8.8% ( p  c 0.001); 
dermatan  sulfate, 63.2 2 20.1% ( p  c 0.01). In  contrast  the  other 
glycosaminoglycans that were tested  had  minimal effects on 
the intensity of the 12sI-IGF-I.IGFBP-5 complex band. They 
were  hyaluronic  acid, 26.5 2 11% ( p ,  not significant);  keratan 
sulfate, 7.4 2 12.9% ( p ,  not significant); chondroitin sulfate A, 
17.2 2 19% ( p ,  not  significant);  and chondroitin sulfate C, 6.7 2 
9.4% ( p ,  not  significant). 
Heparin  has been shown to bind to  several  proteins,  such as 
lipoproteins,  growth  factors, proteases,  and  protease  inhibitors 
(8, 13). Heparin-binding  proteins  usually possess similar hep- 
arin-binding  amino acid  sequence  motifs, including X-B-B-X- 
B-X and/or X-B-B-B-X-X-B-X (B: basic amino acid, X nonbasic 
amino  acid) (13). IGFBPs except for IGFBP-4  possess a t  least 
one of these  putative  heparin-binding  amino acid motifs (14). 
IGFBP-5 and IGFBP-3 have two putative heparin-binding 
amino acid sequences: residues 117s-K-K-G-H-A1R" and  F"-K- 
K-K-Q-C-R-P25" in IGFBP-3 and  residues P139-K-H-T-R-114" and 
F2'-K-R-K-Q-C-K-P2", in IGFBP-5. Therefore, we prepared a 
synthetic  peptide  (termed peptide A) containing  the  residues 
R221-K-G-F-Y-K-R-K-Q-C-K-P-S-R-G-R-K-R238 to  determine 
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FIG. 6. Differences in the inhibitory effects of  various glyco- 
saminoglycans on formation of the IGF-1.IGFBP-5 complex. 'T- 
IGF-I (30,000 cpm/tube) was incubated with 100 ng/ml IGFBP-5 and 
200 pg/ml of each glycosaminoglycan at room temperature.  After  a  1-h 
incubation,  the  samples  were  cross-linked,  electrophoresed,  and  auto- 
radiographed as  described in  the legend  to  Fig. L4. Lune 1, no GAG; 
lane 2, heparin; lune 3, heparan  sulfate; lune 4,  hyaluronic  acid; lune 5, 
keratan  sulfate; lune 6, chondroitin  sulfate A ,  lune 7, dermatan  sulfate; 
lune 8, chondroitin  sulfate C; lune 9, unlabeled  IGF-I,  100 ng/ml. 
whether  the  putative  heparin-binding region (YZs-K-R-K-Q-C- 
K-P'") of IGFBP-5 is responsible for its binding to  heparin. 
Peptide B (A1"-V-K-K-D-R-R-K-K-L-T161), which contains sev- 
eral basic residues  but no putative  heparin-binding region, was 
used as a control. '251-IGF-I was  incubated  with 100 ng/ml of 
IGFBP-5 and  10 pg/ml of heparin  in  the presence or  absence of 
the indicated concentrations of peptide A or  peptide B  (Fig. 7). 
Heparin decreased formation of the  12sI-IGF-I~IGFBP-5 com- 
plex, and complex formation was restored by co-incubation 
with peptide A. In  contrast, peptide  B had no effect strongly, 
suggesting  that  the region of IGFBP-5 encoded by peptide A 
was  important for IGFBP-5 binding  to  heparin. To further de- 
termine specificity an  additional IGFBP-5 peptide  was  tested 
for its capacity to  alter '251-IGF-I~IGFBP-5 complex formation. 
Peptide D, which contains  the P'39-K-H-T-R-1144 sequence, also 
had no effect (data  not shown). In  order  to  rule out the possi- 
bility that peptide  A  directly alters  the  binding of  "'I-IGF-I to 
IGFBP-5, 12sI-IGF-I was  incubated  with 100 ng/ml of IGFBP-5 
and  increasing  concentrations of peptide A in  the  absence of 
heparin,  then cross-linking was performed. Peptide A had no 
effect on 12'I-IGF-I binding  to IGFBP-5 (data  not shown). 
We reported previously that IGFBP-5  bound specifically to 
fibroblast ECM and  that  the  interaction between  IGFBP-5 and 
fibroblast ECM was  inhibited by NaCl (7). Heparin  is a highly 
negatively  charged molecule composed of repeating disaccha- 
rides  with carboxyl and  sulfate  groups (24). Therefore, the  sul- 
fate and/or carboxyl groups of heparin may  be important for 
inhibition of IGF-I.IGFBP-5 complex formation. To examine 
the  importance of the  sulfate  groups, 1251-IGF-I was  incubated 
with 100 ng/ml of IGFBP-5 in  the presence or absence of 200 
pg/ml of various chemically modified heparins. CDSNAc-hepa- 
rin  inhibited IGF-I-IGFBP-5 complex formation, but  its activity 
was considerably decreased compared with heparin (Fig. 8, 
lanes 2 and 4) .  The  mean reduction in  band  intensity compared 
with control in four experiments  was 83 2 3% ( p  < 0.001) for 
heparin  and 16 * 17% ( p ,  not  significant) for CDSNAc heparin. 
NDSNAc-heparin, which retains 0-sulfate groups, was most 
active, but  it  did not  have  an  inhibitory effect that  was  equal  to 
unmodified heparin.  The  mean reduction for the  experiments 
was  52 * 15% ( p  < 0.02). The activity of CDSNS-heparin was 
slightly  greater  than  that of CDSNAc-heparin, but  was signifi- 
cantly  less  than NDSNAc-heparin. The  mean reduction was  21 
+1 17% ( p ,  not  significant).  These  results  indicate that  0-sulfate 
groups of heparin  are  important  to  obtain  inhibitory effects of 
heparin  and  that N-sulfation has only minimal effects on total 
heparin activity. 
We examined  whether  other negatively charged polysaccha- 
ride  substances  that  contain  0-sulfate groups could alter IGF- 
I.IGFBP-5 complex formation. Dextran  sulfate (M, <10,000), 
pentosan polysulfate and fucoidan were tested for activity. "'I- 
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FIG. 7. Reversal  of the heparin effect with an IGFBP-5 peptide 
containing the heparin binding domain. '2511-IGF-I (30,000 cpm/ 
tube)  and 100 ng/ml IGFBP-5 (3.2 nn) were incubated with 10 pg/ml 
heparin  in  the  presence or absence of peptide  A or peptide B a t  room 
temperature for 1 h.  The  samples  were  cross-linked  and  subjected  to 
SDS-PAGE as  described  in  the  legend  to  Fig. L4. Lunes 2-8, heparin,  10 
pg/ml, Lunes 3, 4, and 5, peptide A, 0.27, 2.7, and 27 p ~ ,  respectively; 
lunes 6, 7, and 8, peptide B, 0.27, 2.7, and 27 p ~ ,  respectively. Lune 9, 
unlabeled  IGF-I, 100 ng/ml. 
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the IGF-IeIGFBP-5 complex. '251-IGF-I (30,000 cpdtube)  in 100 pl of 
FIG. 8. The effects of  modified  forms of  heparin on formation  of 
EMEM  supplemented  with 20 mM HEPES,  pH 7.3, was  incubated  with 
100 ng/ml IGFBP-5 and 200 pg/ml of modified heparins  at room tem- 
perature for 1 h,  then  the  samples  were  cross-linked  and  electropho- 
resed as in Fig. LA. Lune 1, no heparin; lune 2, heparin; lune 3, ND- 
SNAc-heparin; lune 4,  CDSNAc-heparin; lune 5, CDSNS-heparin. 
IGF-I was  incubated  with 100 ng/ml IGFBP-5 in  the presence 
or absence of 100 pg/ml of these polyanionic substances. All 
three polyanionio compounds inhibited formation of IGF-I- 
.IGFBP-5 complexes (Fig. 9). The  reductions  in  band  intensities 
were 85% for dextran sulfate, 55% for pentosan polysulfate, 
and 88% for fucoidan. 
DISCUSSION 
In  this  paper we report  that  heparin  inhibits formation of the 
IGF-I.IGFBP-5 complex and  that  this effect can be mimicked 
by heparin-like compounds that contain 0-sulfated  saccharide 
chains. Heparin's activity was detectable, even if the IGF-I- 
.IGFBP-5 complex had been  preformed and occurred a t  heparin 
concentrations as low as 1.0 pg/ml. The effect occurred rapidly, 
since  complete  dissolution of preformed complexes was detect- 
able 15 min  after  the addition of heparin.  The effect appeared 
to be specific, since the formation of complexes between radio- 
labeled  IGF-I and IGFBP-1,  IGFBP-2, or IGFBP-4 could not be 
inhibited by heparin  thus proving that  heparin  was  not non- 
specifically interfering  with  the cross-linking  reaction. 
Heparin  inhibited  the  binding of IGF-I to IGFBP-5 by de- 
creasing  the affinity of IGFBP-5. We hypothesize that binding 
of heparin  to IGFBP-5 leads  to a conformational change  that 
results in a reduction of its affinity for IGF-I and that the 
binding  sites  within IGFBP-5 for heparin  and IGF-I are differ- 
ent.  In  support of this  hypothesis  is  the  experimental observa- 
tion that  heparin  resulted  in a 17-fold reduction in  the affinity 
of IGFBP-5 for IGF-I. Furthermore,  peptide A, which contains 
a putative  heparin binding  domain of IGFBP-5,  inhibited the 
effect of heparin on IGF-I binding  to IGFBP-5. However peptide 
A  did not directly inhibit '2sI-IGF-I binding  to IGFBP-5. This  is 
direct evidence that  the  heparin  binding domain of IGFBP-5 is 
not  the  same  as  the IGF-I binding  site. I t  is still possible that 
IGFBP-5 might bind heparin  through two sites one of which 
contains  the IGF-I binding  site  and  the  other which does  not. 
However, when we tested a synthetic peptide that  contains  the 
only other known potential heparin binding site within IG- 
FBP-5 (e.g. the BBXB sequence), it had no effect on heparin 
inhibition of IGF-I  binding, suggesting  that only one binding 
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FIG. 9. Inhibitory effects of dextran  sulfate,  pentosan  polysul- 
fate,  and  fucoidan on formation  of the IGF-I-IGFBP-5 complex. 
'2sI-IGF-I (30,000 cpdtube)  and IGFBP-5,100 ng/ml, were  added  to 100 
pl of EMEM supplemented  with 20 mM HEPES,  pH 7.3, and  incubated 
in  the presence or absence of 100 pg/ml of each  sulfated  polysaccharide 
at room temperature for 1 h.  Samples  were  then  cross-linked  with DSS, 
and SDS-PAGE was  performed  using a 12.5% gel as  described  under 
"Experimental Procedures." Lune 1, control; lune 2, heparin; lane 3, 
dextran  sulfate; lune 4, pentosan  polysulfate; lune 5, fucoidan; lune 6, 
unlabeled  IGF-I, 100 ng/ml. 
site for heparin was present in IGFBP-5. IGFBP-3, like IG- 
FBP-5, contains the peptide A sequence, and this sequence 
appears  to function as a heparin  binding domain. The affinity 
of IGFBP-3 for IGF-I is also directly lowered by heparin bind- 
ing  but  heparin  concentrations as high as 500 pg/ml  were re- 
quired  to  detect a reduction in 12!jIGF-I.IGFBP-3 band  intensity 
that was equivalent to the reduction in '251-IGF-I.IGFBP-5 
band  intensity  with  10 pg/ml heparin.  In  spite of its  ability  to 
bind weakly to heparin, IGFBP-4 did not show a change in 
'251-IGF-I.IGFBP-4 band  intensity even when 500 pg/ml of hep- 
arin  was  added  indicating  that it did not undergo an  affinity 
shift. IGFBP-4 does not  contain  the  peptide A  sequence sug- 
gesting that  this sequence may be involved in  the affinity shift 
that occurs with  heparin binding. 
Proteoglycans  often  bind other  proteins by forming a bond 
between the glycosaminoglycans and basic amino acid se- 
quences, suggesting that  the basic amino acid groups  in IG- 
FBP-5 might play an  important role in  its  attachment  to hep- 
arin.  Peptide A, which contains a putative  heparin domain from 
positions  225 to 232, completely prevented  the  inhibitory effect 
of heparin on IGF-1.IGFBP-5 complex formation. In  contrast, 
peptide B, which is also highly basic but does not contain a 
heparin binding motif, had no effect. This strongly suggests 
that  the effect of peptide  A is  due  to its BBBXXB motif and  not 
its basic  charge. An additional peptide,  peptide D, which con- 
tains  the BBXB motif that is present  in  many  other  heparin- 
binding  proteins (13) had no effect, suggesting that  the 
BBBXXB motif was  required. However, since a 1000-fold excess 
of peptide  A was  required  to compete for IGFBP-5 binding  to 
heparin, we cannot absolutely exclude that  other regions of 
IGFBP-5 may be involved in  the  heparin IGFBP-5 interaction. 
Heparin-binding proteins such as antithrombin 111, apoli- 
poprotein  E and apolipoprotein B-100 are believed to form a 
helical wheel configuration in which the basic residues are 
clustered asymmetrically on one side of the helical  wheel (13). 
Helical  wheel analysis of the 18-amino  acid  region of IGFBP-5 
that  flanks  the BBBXXB motif in peptide  A (residues 221-238) 
also has  this  characteristic.  In  contrast helical  wheel analysis 
of the regions of IGFBP-5  contained in  peptides B and D  shows 
that  they  have more symmetric  charge  distributions.  Similarly 
IGFBP-1 and -2 contain BBXB motifs, but helical  wheel anal- 
ysis  shows that  their basic residues  are  not  clustered on one 
side of the helical wheel. 
Glycosaminoglycans other  than  heparin  also  inhibited  the 
IGF-I.IGFBP-5 interaction.  The common structural  character- 
istic that is present  in  heparin,  heparan  sulfate,  and  dermatan 
sulfate, but not in the other GAGs that were tested, is the 
presence of 0-sulfate  groups  linked  to  iduronic acid at the 2 or 
3 carbon  positions  (25). Of interest  is  the observation that der- 
matan  sulfate  was by far  the  weakest of these  three compounds 
in inhibiting complex formation. Dermatan sulfate contains 
fewer 0-sulfated groups that are linked to the 2 carbon of 
iduronic acid as compared with heparan sulfate or heparin, 
suggesting that  the  number of 0-sulfate  groups  that  are linked 
in  this  manner is also  important.  The  importance of 0-sulfates 
is further  substantiated by our  findings  with chemically modi- 
fied heparins which showed that completely desulfated  heparin 
or completely desulfated,  N-resulfated  heparin  had  either no 
activity or very minimal activity. To determine  whether  idu- 
ronic acid was  the only type of saccharide that would have 
activity, compounds with different saccharide  units  but which 
contained  0-sulfate  groups were tested.  Dextran  sulfate, pen- 
tosan polysulfate, and fucoidan all  had significant inhibitory 
activity, further  indicating  that  the  type of saccharide  ring  was 
not  important  but  that  0-sulfate  groups  in  either  the 2 or 3 
positions  were necessary. 
Heparin-like GAGs, such as  heparan  sulfate  and  dermatan 
sulfate,  are  present on cell surfaces  and  in ECM. Numerous 
cross-linking studies  have shown that both IGFBP-3 and IG- 
FBP-5 are cell surface associated. However unlike IGFBP-1, 
which can bind to cell surfaces  through a specific interaction 
between its RGD sequence and  an  integrin  receptor (26), these 
forms of IGFBPs  have no known receptor. Therefore  their bind- 
ing  to cell surface or to ECM could be mediated by binding of 
basic amino acid groups  in  these  IGFBPs  to specific proteogly- 
cans on the cell surface or in the ECM. We have reported 
previously that  the affinity of IGFBP-5 for IGF-I is 8-fold lower 
when it is associated with ECM (7)  and  that  the affinity of 
IGFBP-3  for  IGF-I is lowered 12-fold when i t  is bound to cell 
surfaces (27).  Likewise Martin et al. (28)  reported recently that 
when  human fibroblast cells were incubated  with  heparin,  the 
amount of IGF bound to cell surface-associated  IGFBP-3 was 
markedly decreased. The  mechanism by which  IGFBP-5 bind- 
ing  to ECM or IGFBP-3 binding  to cell surface lowers their 
affinities  for  IGF-I is  unknown,  but  our  findings  suggest  that 
heparin-like molecules cause a  direct  reduction in affinity prob- 
ably through a conformational change for IGFBP-5 and possi- 
bly for IGFBP-3. Such a conformational change  has been pro- 
posed for vitronectin association with  heparin (13). Likewise 
exposure of heparin  to  antithrombin I11 also results  in a major 
conformational change (29). Our data showing that heparin 
and IGF-I have different binding  sites on IGFBP-5 are  in  sup- 
port of this hypothesis. The significance of this affinity shift  to 
IGFBP-5  modulation of IGF-I  action is unknown; however, in 
previous experiments we have shown that when IGFBP-5 is 
associated with ECM, it is capable of potentiating  the ffects of 
IGF-I on cell growth.  A  simple model would be that reduction in 
its affinity for IGF-I allows for more sustained  release of IGF-I 
to  receptors  and that  this slow time-dependent  release  results 
in  potentiation of the cell growth  response. As noted previously, 
modulation of growth  factor  activity by GAGs has been shown 
in  several in vitro test  systems (10, 11) 
In  addition  to dissolution of this complex following cell sur- 
face or ECM association, heparin-like compounds may also re- 
sult  in  changes  in IGF-I binding to serum-binding proteins. 
Addition of heparin  to  serum  results  in dissolution of the acid 
labile  subunit.IGFBP-3.IGF-I complex (15, 30). The molecular 
mechanism by which  IGF-I leaves  this  tightly bound complex 
and is transported  out of the  extravascular space is unknown, 
but  the presence of glycosaminoglycans either  in  serum (15) or 
o  endothelial cell surfaces (16) has been proposed as a mech- 
anism for dissolution of the complex. This might operate 
through a similar affinity-lowering effect that  is dependent 
upon heparin binding. 
Glycosaminoglycans  Inhibit  IGF-I.IGFBP  Complex Formation 20393 
In  summary the significance of IGFBP-3- and IGFBP-5-bind- 
ing glycosaminoglycans in modulating IGF-I interaction with 
cell surface receptors is incompletely defined. These studies 
provide  a  format  for analyzing mechanisms of  how the affinity 
of the IGF-binding proteins might be altered by heparin or 
GAG interactions. Since reductions in IGFBP affinity by de- 
phosphorylation or proteolysis have been shown to result in 
potentiation of  IGF-I action in several systems, determination 
of the effect of this heparin-IGFBP interaction on IGF-I-medi- 
ated actions will be important  future studies. 
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